These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30877622)

  • 1. DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    CNS Drugs; 2019 Apr; 33(4):375-382. PubMed ID: 30877622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):69. PubMed ID: 30112726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):70. PubMed ID: 30112725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
    Munjal S; Brand-Schieber E; Allenby K; Spierings ELH; Cady RK; Rapoport AM
    J Headache Pain; 2017 Dec; 18(1):31. PubMed ID: 28251391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine.
    Cady RK; Munjal S; Cady RJ; Manley HR; Brand-Schieber E
    J Headache Pain; 2017 Dec; 18(1):17. PubMed ID: 28176235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
    Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
    Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Tepper SJ; Dodick DW
    Headache; 2020 Jan; 60(1):58-70. PubMed ID: 31647577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.
    Winner P; Rothner AD; Saper J; Nett R; Asgharnejad M; Laurenza A; Austin R; Peykamian M
    Pediatrics; 2000 Nov; 106(5):989-97. PubMed ID: 11061765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
    Winner P; Rothner AD; Wooten JD; Webster C; Ames M
    Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
    Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
    Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies.
    Ryan R; Elkind A; Baker CC; Mullican W; DeBussey S; Asgharnejad M
    Neurology; 1997 Nov; 49(5):1225-30. PubMed ID: 9371898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
    Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
    Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
    Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
    Lipton RB; McGinley JS; Shulman KJ; Wirth RJ; Buse DC
    Headache; 2017 Nov; 57(10):1570-1582. PubMed ID: 28880380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine.
    Barbanti P; Carpay JA; Kwong WJ; Ahmad F; Boswell D
    Curr Med Res Opin; 2004 Dec; 20(12):2021-9. PubMed ID: 15701219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
    Croop R; Madonia J; Stock DA; Thiry A; Forshaw M; Murphy A; Coric V; Lipton RB
    Headache; 2022 Oct; 62(9):1153-1163. PubMed ID: 36239038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.